Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Tewari on Key Differences Between Racial Subgroups in Prostate Cancer

April 23rd 2021

Ashutosh K. Tewari, MD, discusses some of the key differences between racial subgroups in prostate cancer.

Dr. Tewari on the Hallmarks of Cancer in Black Men With Prostate Cancer

April 22nd 2021

Ashutosh K. Tewari, MD, discusses the hallmarks of cancer among Black men with prostate cancer.

Dr. Burgess on the FDA Accelerated Approval of Rucaparib in BRCA+ mCRPC

April 22nd 2021

Earle Burgess, MD, discusses the FDA accelerated approval of rucaparib in BRCA-positive metastatic castration-resistant prostate cancer.

Dr. Tewari on the Potential Benefits of a Mobile MRI Unit in Prostate Cancer

April 21st 2021

Ashutosh K. Tewari, MD, director, Department of Urology, Mount Sinai, discusses the potential benefits of a mobile MRI unit in prostate cancer.

Dr. Ward on the Debate Over Adjuvant Radiation Therapy in Prostate Cancer

April 20th 2021

Matthew C. Ward, MD, discusses the debate over adjuvant radiation therapy in prostate cancer.

Regulatory Submissions for Apalutamide Combo in Metastatic CRPC Will Not Be Pursued

April 20th 2021

Regulatory submissions for the combination of apalutamide plus abiraterone acetate and prednisone in the treatment of chemotherapy-naïve patients with metastatic castration-resistant prostate cancer will not be pursued.

Dr. Zhu on the Role of ADT in Pelvic Node–Positive Prostate Cancer

April 20th 2021

Jason Zhu, MD, discusses the role of androgen deprivation therapy in patients with pelvic node–positive prostate cancer.

Dr. Burgess on Treatment Considerations for PARP Inhibitors in Prostate Cancer

April 16th 2021

Earle Burgess, MD, discusses treatment considerations for PARP inhibitor use in patients with prostate cancer.

Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations

April 13th 2021

Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.

Nivolumab/Ipilimumab Showcases Significant Antitumor Activity in Metastatic CRPC

April 10th 2021

Nivolumab plus ipilimumab was found to induce significant antitumor activity when administered to patients with metastatic castration-resistant prostate cancer and immunogenic signature.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

Healthy Lifestyle May Reduce Likelihood of Lethal Prostate Cancer Among Those With High Genetic Risk

April 10th 2021

Maintaining a healthy lifestyle was found to reduce the likelihood of developing metastatic disease or dying of prostate cancer among men who had a high genetic risk.

PARP Inhibitors Could Help Craft Better Personalized Medicine in Prostate Cancer

April 7th 2021

Tanya Dorff, MD, discusses how the FDA approvals of olaparib and rucaparib have paved the way for additional research with PARP inhibitors in metastatic castration-resistant prostate cancer.

Dr. Piliè on the Benefit of Second-Generation AR Inhibitors in Nonmetastatic CRPC

April 6th 2021

Patrick Piliè, MD, discusses the benefit of second-generation androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Shore on Future Research Directions with Darolutamide in Prostate Cancer

April 1st 2021

Neal D. Shore, MD, FACS, discusses future research directions with darolutamide for the treatment of patients with prostate cancer.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Novel NTD Inhibitor EPI-7386 Plus Enzalutamide Under Evaluation in mCRPC

March 31st 2021

The first-in-class N-terminal domain androgen receptor inhibitor EPI-7386 is being examined in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer as part of a phase 1/2 trial.

Enzalutamide Granted Positive EU Opinion for Metastatic Hormone-Sensitive Prostate Cancer

March 30th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend an additional indication of enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

177Lu-PSMA-617 Improves OS and rPFS Over Best Standard of Care in Advanced Prostate Cancer

March 23rd 2021

The addition of the targeted radioligand therapy 177Lu-PSMA-617 to best standard of care was found to significantly improve overall survival and radiographic progression-free survival over best standard care alone in patients with prostate specific membrane antigen–positive metastatic castration-resistant prostate cancer, meeting both primary end points of the phase 3 VISION trial.

Dr. Dorff on the Importance of Somatic Testing in mCRPC

March 22nd 2021

Tanya Dorff, MD, discusses the importance of somatic testing in metastatic castration-resistant prostate cancer.